Insmed
INSM
224 hedge funds and large institutions have $2.89B invested in Insmed in 2022 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 89 increasing their positions, 70 reducing their positions, and 19 closing their positions.
141% more call options, than puts
Call options by funds: $3.96M | Put options by funds: $1.65M
68% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 19
27% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 70
5% more funds holding
Funds holding: 214 → 224 (+10)
2.21% more ownership
Funds ownership: 104.2% → 106.41% (+2.2%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
13% less capital invested
Capital invested by funds: $3.31B → $2.89B (-$418M)
Top Buyers
Top Sellers
INSM Hedge Fund Activity: Q1 2022 in Review
224 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Insmed (INSM) for Q1 2022, worth a combined $2.89B — down 13% from $3.31B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new INSM positions and 19 closed out — a net gain of 13 holders — while 89 added to existing stakes and 70 trimmed.
The largest buyer was Assenagon Asset Management, adding an estimated $18.5M. The largest seller was William Blair Investment Management, cutting an estimated $30.6M.
- 224 institutional investors held Insmed (INSM) as of Q1 2022, up from 214 in Q4 2021.
- Funds reported $2.89B of Insmed stock for Q1 2022, down 13% quarter-over-quarter.
- 32 funds opened new Insmed positions in Q1 2022 and 19 closed out, a net change of +13 holders.
- The largest Insmed buyer in Q1 2022 was Assenagon Asset Management, an estimated $18.5M added.
- The largest Insmed seller in Q1 2022 was William Blair Investment Management, an estimated $30.6M sold.
Based on aggregated 13F filings for Q1 2022.